mlc1501

Stroke

Moleac Pte Ltd.Phase 2/3Active

B

61/ 100

Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence: 59/ 100
Competitive Position: 65/ 100

Competitive context

132 Active assets in the Stroke cohort.

Asset / Sponsor	Phase	Rating
INCOBOTULINUMTOXINA Parc de Salut Mar	Phase 4	BBB
Aggrenox Boehringer Ingelheim	Phase 4	BBB
ATENOLOL Northern California Institute of Research and Education	Phase 4	BBB
Dextromethorphan University of Florida	Phase 4	BBB
Nerinetide NoNO Inc.	Phase 3	BBB

View all 50 →

Same molecule, other indications

mlc1501 is also rated in:

ischemic strokeDormant

BB

Indicative ·

67 / 100

Strokes ThromboticDormant

BB

Indicative ·

67 / 100

intracranial embolismDormant

NR

Indicative ·

/ 100

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.